サンプル依頼リスト カート
  • English
  • Korean
表紙：コンパニオン診断の世界市場-2023年～2030年
市場調査レポート
商品コード
1316271

コンパニオン診断の世界市場-2023年～2030年

Global Companion Diagnostics Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
コンパニオン診断の世界市場-2023年～2030年
出版日: 2023年07月27日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

コンパニオン診断の世界市場は、2022年に61億米ドルに達し、2030年には150億米ドルまで成長すると予測されています。コンパニオン診断の世界市場は、予測期間（2023-2030年）にCAGR 12.2%を示すと予測されています。

コンパニオン診断市場の動向には、コンパニオン診断の利用拡大、製薬企業と診断薬企業の共同研究、次世代シーケンシング（NGS）技術の統合などが含まれます。

コンパニオン診断には、組織生検、血液サンプル、その他の体液など、様々な種類の患者サンプルの分析が含まれます。これらのサンプルは、特定のバイオマーカー、遺伝子変異、または患者の疾患や治療反応に関する洞察を提供できるその他の分子特性について検査されます。

さらに、ゲノミクスと分子生物学の進歩、慢性疾患の早期発見と予防への関心の高まり、標的治療へのニーズの高まりが、予測期間中に市場を牽引すると予想される要因です。

市場力学

コンパニオン診断検査に対するFDA認可の増加がコンパニオン診断市場の世界成長を促進すると予想される

2022年12月、RAS GTPaseファミリー阻害薬アダグラシブ（商品名クラザティ）は、少なくとも1回の前治療が全身療法であるKRAS G12C変異の局所進行性または転移性非小細胞肺がん（NSCLC）成人患者の治療薬として早期承認を取得しました。アダグラシブの承認と同時に、組織検査用のQIAGEN therascreen KRAS RGQ PCRキットと血漿検査用のAgilent Resolution ctDx FIRST Assayの2つのコンパニオン診断も承認されました。

アダグラシブの承認は、KRAS G12C変異が確認された局所進行性または転移性NSCLC患者116人を対象とした多施設、単群、非盲検試験であるKRYSTAL-1臨床試験のデータに基づいています。

本試験の第2相コホートにおいて、ベースライン時に測定可能な病変を有する患者112人の客観的奏効率（ORR）は43％でした（95％信頼区間[CI]：33.5、52.6）。奏効期間（DoR）中央値は8.5ヵ月（95％信頼区間：6.2、13.8）、無増悪生存期間（PFS）中央値は6.5ヵ月（95％信頼区間：4.7、8.4）でした。治療歴のある安定した中枢神経系転移を有する33人の患者のうち、頭蓋内ORRが確認されたのは33.3％でした。このように、上記の要因により、予測期間中、市場は牽引役となることが期待されます。

コンパニオン診断と予測バイオマーカーを通じた新興国市場の開拓と個別化治療が世界のコンパニオン診断市場の成長を牽引すると期待される

有望な抗がん剤の後期臨床試験で見られる高い失敗率は、薬剤開発と腫瘍に対する有効性の評価のための代替戦略の探求を促しています。現在、臨床現場で一般的に使用されている予測バイオマーカーはわずかであり、多くの場合レトロスペクティブに確立されています。

しかし、コンパニオン診断の出現は、前臨床の早い段階で予測バイオマーカーを同定し、薬剤開発プロセスを通じて検証することにより、薬剤開発を迅速化する機会を提供します。コンパニオン診断は、腫瘍の遺伝子構成や生物学的特徴に基づいて、特定の患者集団に対する新薬の有効性と安全性を評価するために前臨床段階で使用される検査です。

Spigelらによって行われた最近の研究では、前治療歴のある非小細胞肺がん患者を対象に、エルロチニブとMetMab（METを標的とするモノクローナル抗体）の併用療法とエルロチニブとプラセボの併用療法を検討した無作為化第II相試験の結果が報告されました。この試験では、蛍光in situハイブリダイゼーション（FISH）と免疫組織化学（IHC）を用いて腫瘍組織におけるcMET発現を評価しました。その結果、エルロチニブにMetMabを追加することで、cMET発現量の高い患者においてのみ、無増悪生存期間と全生存期間が有意に改善することが示されました。

IHCはMetMabの有益性を予測する最も感度の高い因子でした。一方、cMET発現量が低い患者はMetMabの恩恵を受けず、エルロチニブ単独で治療した患者に比べ、転帰が有意に不良でした。この研究は、予測バイオマーカーの前向き評価を示し、実験的治療の評価におけるコンパニオン診断の重要性を強調しています。

早期臨床試験後の腫瘍特異性に焦点を当てた薬剤開発を促進するためには、前臨床試験を実施してバイオマーカーを同定し、その評価のための検査を開発すべきです。このアプローチは、早期臨床試験で臨床的に評価され、ランダム化第II相および第III相試験で前向きに検証される診断予測シグネチャーの開発に道を開くと見込まれます。このように、上記の要因により、予測期間中、同市場は拡大すると予想されます。

精密医療におけるコンパニオン診断に関連する欠点がコンパニオン診断の世界市場の成長を妨げると予想される

コンパニオン診断の開発は、特に疾患や薬剤のメカニズムに関する情報が限られている場合、大きな課題となり得えます。薬剤と診断薬の開発は別々の道をたどることが多く、臨床試験中に両者の整合性をとるのが遅れる可能性があります。

さらに、偽陽性や偽陰性はその有用性を損なう可能性があるため、診断テストの信頼性は極めて重要です。もう一つの障害は、ヘルスケアシステムによる償還が限られていることで、コンパニオン診断の普及を妨げています。コンパニオン診断に関する知的財産法は医薬品に関するものとは異なるため、安価であるが検証されていない検査の作成と販売が可能です。

このような課題にもかかわらず、コンパニオン診断はプレシジョン・メディシンの将来を担うものと考えられており、コンパニオン診断の開発および検査に対するより良いサポートが提供されるような変化が望まれます。したがって、上記の要因により、予測期間中、市場は低迷すると予想されます。

COVID-19影響分析

COVID-19の早期診断は、ウイルスの影響を受けた患者に適切な治療法を見つけるのに役立つため、市場では不可欠となっています。COVID-19の診断に最も一般的に使用され信頼性の高い検査は、鼻咽頭ぬぐい液または咽頭ぬぐい液を含むその他の上気道検体を用いて実施されるポリメラーゼ連鎖反応（PCR）検査です。したがって、ポリメラーゼ連鎖反応（PCR）を用いた疾患診断は、この疾患を管理するための主要な焦点として浮上しました。

コンパニオン診断市場は、様々な疾患に対する新たなバイオマーカーの開拓、標的治療の研究開発の増加、新興国市場での認知度向上によるオーダーメイド医療への需要の増加、アンメットがん治療ニーズの増加により、大幅な成長が見込まれています。例えば、Systematic Reviews in Pharmacyに掲載された2022年の論文によると、SARS-CoV-2ワクチン接種のためのコンパニオン診断が、COVID-19ワクチン接種戦略を強化するために検討されていました。

これらのコンパニオン診断には血清学的抗体検査が用いられました。研究のその段階で、SARS-CoV-2ワクチンのコンパニオン診断には大きな利点があることが判明しました。特定の検査を組み合わせて免疫反応をモニターすることで、これらの診断薬はCOVID-19に対する耐久性と信頼性のある防御を提供し、医療上の安心を提供することを目指しました。この論文は、ワクチン接種スケジュールの最適化とウイルスに対する効果的な免疫防御の確保におけるコンパニオン診断の潜在的な利点を強調しています。

ロシア・ウクライナ紛争分析

ロシアとウクライナの紛争はコンパニオン診断市場に影響を与えています。紛争はウクライナのヘルスケアシステムとインフラを混乱させ、コンパニオン診断を含む医療サービスと供給へのアクセスに課題をもたらしました。

戦争は同地域の研究開発活動にとって不安定な環境を作り出し、コンパニオン診断の進歩や進展に影響を与えています。限られた資源と軍事活動への資金流用が、コンパニオン診断の開発と実施を含むヘルスケアと生物医学研究への投資を妨げていると考えられます。

さらに、紛争は人口の移動と移住をもたらし、患者ケアとヘルスケア提供システムの混乱を引き起こしています。このような混乱はコンパニオン診断の需要に影響を与え、必要とする人々へのアクセスを制限する可能性があります。

さらに、戦争に起因する地政学的緊張や経済的不安定は、コンパニオン診断市場における国際的な協力関係や投資に広範な影響を及ぼす可能性があります。不確実性と地政学的リスクは、海外の投資家や企業がウクライナ市場に参入することを躊躇させ、同地域におけるコンパニオン診断の利用可能性と導入に影響を与える可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • コンパニオン診断のための新規フレームワークの進展
      • 次世代シーケンサーによるコンパニオン診断のためのパートナーシップの拡大
    • 抑制要因
      • コンパニオン診断開発に伴う課題
    • 機会
      • 市場プレイヤー間のコラボレーションとイノベーション
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • アンメットニーズ
  • 規制分析

第6章 COVID-19分析

第7章 ロシア・ウクライナ戦争分析

第8章 製品・サービス別

  • アッセイ
  • キット・試薬
  • ソフトウェア＆サービス

第9章 技術別

  • 免疫組織化学（IHC）
  • ポリメラーゼ連鎖反応（PCR）
  • インサイチュハイブリダイゼーション（ISH）
  • 次世代シーケンシング
  • その他

第10章 適応症別

  • 心血管
  • 神経疾患
  • がん
    • 乳がん
    • 肺がん
    • 大腸がん
    • 黒色腫
    • 胃がん
    • その他
  • 炎症および自己免疫疾患
  • その他

第11章 エンドユーザー別

  • 製薬・バイオ医薬品企業
  • 受託研究機関
  • その他

第12章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第13章 競合情勢

  • 競合シナリオ
  • 製品ベンチマーク
  • 企業シェア分析
  • 主な発展と戦略

第14章 企業プロファイル

  • F. Hoffmann-La Roche Ltd.
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Thermo Fisher Scientific, Inc.
  • Abbott Laboratories, Inc.
  • Biomerieux SA
  • Siemens Healthcare
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation（Beckman Coulter Inc.）
  • Guardant Health
  • Illumina Inc.

第15章 付録

目次
Product Code: CD224

Market Overview

The global companion diagnostics market reached US$ 6.1 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 15.0 billion by 2030. The global companion diagnostics market is expected to exhibit a CAGR of 12.2% during the forecast period (2023-2030).

The trends in the global companion diagnostic market include the rising utilization of companion diagnostics, the collaborative efforts between pharmaceutical and diagnostic companies, and the integration of Next-Generation Sequencing (NGS) technology within this market.

Companion diagnostics involve analyzing various types of patient samples, such as tissue biopsies, blood samples, or other bodily fluids. These samples are tested for specific biomarkers, genetic mutations, or other molecular characteristics that can provide insights into a patient's disease or treatment response.

Furthermore, the advancements in genomics and molecular biology, the increased focus on early detection and prevention of chronic diseases, and the growing need for targeted therapies are the factors expected to drive the market over the forecast period.

Market Dynamics

The Increasing FDA approvals for Companion Diagnostic Tests are Expected to Drive the Global Companion Diagnostics Market Growth

In December 2022, the RAS GTPase family inhibitor adagrasib (brand name Krazati) received accelerated approval for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have undergone at least one prior systemic therapy. Alongside the approval of adagrasib, two companion diagnostic tests were also approved, the QIAGEN therascreen KRAS RGQ PCR kit for tissue testing and the Agilent Resolution ctDx FIRST Assay for plasma testing.

The approval of adagrasib was based on data from the KRYSTAL-1 clinical trial, which was a multicenter, single-arm, open-label study involving 116 patients with locally advanced or metastatic NSCLC harboring confirmed KRAS G12C mutations.

In a phase 2 cohort of the trial, the objective response rate (ORR) was 43% among 112 patients with measurable disease at baseline (95% confidence interval [CI]: 33.5, 52.6). The median duration of response (DoR) was 8.5 months (95% CI: 6.2, 13.8), and the median progression-free survival (PFS) was 6.5 months (95% CI: 4.7, 8.4). Among 33 patients with previously treated stable central nervous system metastases, the confirmed intracranial ORR was 33.3%. Thus, owing to the above factors, the market is expected to drive over the forecast period.

Advancing Drug Development and Personalized Treatment through Companion Diagnostics and Predictive Biomarkers are Expected to Drive the Global Companion Diagnostics Market Growth

The high failure rates seen in late-stage clinical trials for promising anti-cancer drugs have prompted the exploration of alternative strategies for drug development and the evaluation of their effectiveness against tumors. Currently, only a few predictive biomarkers are commonly used in clinical practice, often established retrospectively.

However, the emergence of companion diagnostics provides an opportunity to expedite drug development by identifying predictive biomarkers early in the preclinical stages and validating them throughout the drug development process. Companion diagnostics are tests used during preclinical stages to assess the efficacy and safety of new drugs for specific patient populations based on the genetic makeup and biological characteristics of the tumor.

A recent study conducted by Spigel et al. reported the results of a randomized phase II trial investigating the combination of erlotinib and MetMab (a monoclonal antibody targeting MET) versus erlotinib plus placebo in previously treated non-small cell lung cancer patients. The study involved assessing cMET expression in tumor tissue using fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). The findings demonstrated that adding MetMab to erlotinib significantly improved progression-free and overall survival only in patients with high cMET expression levels.

IHC was found to be the most sensitive predictor of the benefits of MetMab. On the other hand, patients with low cMET expression did not benefit from MetMab and had significantly worse outcomes compared to those treated with erlotinib alone. This study illustrates the prospective assessment of a predictive biomarker and highlights the importance of companion diagnostics in evaluating experimental treatments.

To facilitate drug development with a focus on tumor specificity after early clinical trials, preclinical studies should be conducted to identify biomarkers and develop tests for their evaluation. This approach will pave the way for the development of diagnostic predictive signatures to be clinically evaluated in early trials and prospectively validated in randomized phase II and III studies. Thus, owing to the above factors, the market is expected to drive over the forecast period.

Drawbacks Associated with Companion Diagnostics in Precision Medicine are Expected to Hamper the Global Companion Diagnostics Market Growth

Developing companion diagnostics can be a significant challenge, especially when there is limited information about the disease or drug mechanism. Drug and diagnostics development often follow separate paths, leading to potential delays in aligning them during clinical trials.

Additionally, the reliability of the diagnostic test is crucial, as false positive or negative results can undermine its utility. Another obstacle is the limited reimbursement coverage by healthcare systems, which discourages the widespread use of companion diagnostics. Intellectual property laws for companion diagnostics differ from those for medicinal products, allowing the creation and marketing of cheaper but unvalidated tests.

Despite these challenges, companion diagnostics are considered the future of precision medicine, and it is hoped that changes will be made to provide better support for their development and testing. Hence, owing to the above factors, the market is expected to hamper over the forecast period.

COVID-19 Impact Analysis

Early diagnosis of COVID-19 is becoming essential in the market, as it can help find the right treatment for patients impacted by the virus. The most commonly used and reliable test for diagnosis of COVID-19 is the polymerase chain reaction (PCR) test performed using nasopharyngeal swabs or other upper respiratory tract specimens, including throat swabs. Thus, the disease diagnosis using polymerase chain reaction (PCR) emerged as a major focus for managing the disease.

The companion diagnostics market is expected to experience substantial growth due to the development of new biomarkers for various diseases, a rise in R&D of targeted therapies, an increase in demand for customized medicine with increased recognition in developing markets, and a higher number of unmet cancer care needs. For instance, according to a 2022 article published in Systematic Reviews in Pharmacy, companion diagnostics for SARS-CoV-2 vaccination were being explored to enhance COVID-19 vaccination strategies.

These companion diagnostics involved the use of serological antibody tests. At that stage of research, SARS-CoV-2 vaccine companion diagnostics were found to provide significant advantages. By monitoring the immune response through specific test combinations, these diagnostics aimed to offer durable and reliable protection against COVID-19, thus providing medical reassurance. The article highlighted the potential benefits of companion diagnostics in optimizing vaccination schedules and ensuring effective immune protection against the virus.

Russia-Ukraine Conflict Analysis

The Russian-Ukraine war has had an impact on the companion diagnostics market. The conflict has disrupted healthcare systems and infrastructure in Ukraine, leading to challenges in accessing medical services and supplies, including companion diagnostics.

The war has created an unstable environment for research and development activities in the region, affecting the progress and advancement of companion diagnostics. Limited resources and the diversion of funds towards military efforts have likely hindered investments in healthcare and biomedical research, including the development and implementation of companion diagnostics.

Additionally, the conflict has resulted in population displacement and migration, causing disruptions in patient care and healthcare delivery systems. This disruption can impact the demand for companion diagnostics and limit their accessibility to individuals in need.

Moreover, the geopolitical tensions and economic instability resulting from the war can have broader implications for international collaborations and investments in the companion diagnostics market. Uncertainty and geopolitical risks can deter foreign investors and companies from engaging in the Ukrainian market, potentially impacting the availability and adoption of companion diagnostics in the region.

Segment Analysis

The global companion diagnostics market is segmented based on product & services, technology, indication, end user, and region.

Cancer from the Indication Segment Account for 35.7% of the Market Share Owing to the Increasing Prevalence of Cancer, Growing Product launches, and Increasing Partnership among Market Players

According to World Health Organization Report 2022, cancer remains a leading global cause of death, resulting in nearly 10 million fatalities in 2020. The highest number of new cancer cases in 2020 were observed in breast cancer (2.26 million cases), lung cancer (2.21 million cases), colon and rectal cancer (1.93 million cases), prostate cancer (1.41 million cases), non-melanoma skin cancer (1.20 million cases), and stomach cancer (1.09 million cases). Regarding cancer-related deaths in 2020, lung cancer was the primary cause with 1.80 million deaths, followed by colon and rectal cancer (916,000 deaths), liver cancer (830,000 deaths), stomach cancer (769,000 deaths), and breast cancer (685,000 deaths).

Furthermore, each year approximately 400,000 children are diagnosed with cancer, with the most common types varying across different countries. Notably, cervical cancer was identified as the most prevalent type in 23 countries.

Additionally, on March 9, 2023, QIAGEN N.V. announced a strategic partnership with Servier, a global pharmaceutical group. The partnership aims to develop a companion diagnostic test for TIBSOVO, a medication used in the treatment of acute myeloid leukemia (AML), a type of blood cancer. TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor.

As part of the collaboration, QIAGEN will be responsible for the development and validation of a real-time in vitro PCR test. This test will be designed to detect IDH1 gene mutations in AML patients using whole blood and bone marrow aspirate samples. The companion diagnostic will be compatible with the QIAGEN Rotor-Gene Q MDx device, a widely used platform in laboratories worldwide.

QIAGEN's regulatory teams will provide their expertise to support the clinical validation of the companion diagnostic and seek its approval in the United States, the European Union, and Japan. This partnership aims to advance personalized medicine in the field of AML treatment by enabling the identification of patients who are likely to benefit from TIBSOVO based on their IDH1 gene mutation status.

Geographical Analysis

North America Accounted for Approximately 39.8% of the Market Share Owing to the Increasing FDA Approvals, Presence of Key Players, and Growing Development and Validation of a Therapeutic Drug and Diagnostic Test

On May 4, 2023, Foundation Medicine, Inc., a leader in molecular profiling for cancer, announced that it received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne Liquid CDx to be used as a companion diagnostic for EXKIVITY (mobocertinib), which is currently FDA-approved for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

Similarly, On May 31, 2023, the Food and Drug Administration approved olaparib (Lynparza, AstraZeneca Pharmaceuticals LP) with abiraterone and prednisone (or prednisolone) for adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC), as determined by an FDA-approved companion diagnostic test.

Furthermore, Experts from Memorial Sloan Kettering Cancer Center (MSK) shared their recent clinical, translational, and foundational cancer research findings at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, Florida, held from April 14 to 19.

The presentations included significant advancements in clinical research with implications for patients with gastric and gastroesophageal junction cancers, as well as KRAS G12C-mutated cancers. Another notable development was the introduction of a new prognostic risk calculator for patients with myelodysplastic syndromes (MDS).

In addition, MSK researchers showcased their latest work in various cutting-edge areas of translational and foundational cancer research. These included translating predictable patterns in copy number alterations in p53-deficient cancers into clinical applications, gaining insights into the evolution of pancreatic cancer through single-nucleus DNA sequencing, and exploring the use of engineered human leukocyte antigen-independent T cell receptor (HIT) T cells to overcome kidney cancer.

Competitive Landscape

The major global players in the market include: F. Hoffmann-La Roche Ltd., Agilent Technologies, Inc., Qiagen N.V., Thermo Fisher Scientific, Inc., Abbott Laboratories, Inc., Biomerieux SA, Siemens Healthcare, Thermo Fisher Scientific Inc., Danaher Corporation (Beckman Coulter Inc.), Guardant Health, and Illumina Inc. among others.

Why Purchase the Report?

  • To visualize the global companion diagnostics market segmentation based on the product & services, technology, indication, end-user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of companion diagnostics market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global companion diagnostics market report would provide approximately 69 tables, 71 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product & Services
  • 3.2. Snippet by Technology
  • 3.3. Snippet by Indication
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Advancing Novel Frameworks for Companion Diagnostics
      • 4.1.1.2. Growing Partnerships for Advance Next-Generation Sequencing Companion Diagnostics
    • 4.1.2. Restraints
      • 4.1.2.1. Challenges Associated with Companion Diagnostic Development
    • 4.1.3. Opportunity
      • 4.1.3.1. Collaboration and Innovation Among Market Players
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. By Product & Services

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Services
    • 8.1.2. Market Attractiveness Index, By Product & Services
  • 8.2. Assays*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Kits & Reagents
  • 8.4. Software & Services

9. By Technology

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.1.2. Market Attractiveness Index, By Technology
  • 9.2. Immunohistochemistry (IHC)*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Polymerase Chain Reaction (PCR)
  • 9.4. In-situ Hybridization (ISH)
  • 9.5. Next-generation Sequencing
  • 9.6. Others

10. By Indication

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.1.2. Market Attractiveness Index, By Indication
  • 10.2. Cardiovascular*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Neurological Diseases
  • 10.4. Cancer
    • 10.4.1. Breast Cancer
    • 10.4.2. Lung Cancer
    • 10.4.3. Colorectal Cancer
    • 10.4.4. Melanoma
    • 10.4.5. Gastric Cancer
    • 10.4.6. Others
  • 10.5. Inflammation and Autoimmune Diseases
  • 10.6. Others

11. By End User

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.1.2. Market Attractiveness Index, By End User
  • 11.2. Pharmaceutical & Biopharmaceutical Companies*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Contract Research Organizations
  • 11.4. Others

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
    • 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.2.7.1. U.S.
      • 12.2.7.2. Canada
      • 12.2.7.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
    • 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.3.7.1. Germany
      • 12.3.7.2. U.K.
      • 12.3.7.3. France
      • 12.3.7.4. Italy
      • 12.3.7.5. Spain
      • 12.3.7.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
    • 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.4.7.1. Brazil
      • 12.4.7.2. Argentina
      • 12.4.7.3. Rest of South America
  • 12.5. Asia Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
    • 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.5.7.1. China
      • 12.5.7.2. India
      • 12.5.7.3. Japan
      • 12.5.7.4. Australia
      • 12.5.7.5. Rest of Asia Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
    • 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

13. Competitive Landscape

  • 13.1. Competitive Scenario
  • 13.2. Product Benchmarking
  • 13.3. Company Share Analysis
  • 13.4. Key Developments and Strategies

14. Company Profiles

  • 14.1. F. Hoffmann-La Roche Ltd. *
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Financial Overview
    • 14.1.4. Key Developments
  • 14.2. Agilent Technologies, Inc.
  • 14.3. Qiagen N.V.
  • 14.4. Thermo Fisher Scientific, Inc.
  • 14.5. Abbott Laboratories, Inc.
  • 14.6. Biomerieux SA
  • 14.7. Siemens Healthcare
  • 14.8. Thermo Fisher Scientific Inc.
  • 14.9. Danaher Corporation (Beckman Coulter Inc.)
  • 14.10. Guardant Health
  • 14.11. Illumina Inc.

LIST NOT EXHAUSTIVE

15. Appendix

  • 15.1. About Us and Services
  • 15.2. Contact Us